08:56 AM EDT, 07/08/2025 (MT Newswires) -- Humacyte ( HUMA ) said Tuesday its Symvess bioengineered vessel has been approved for listing in the US Defense Logistics Agency's Electronic Catalog.

The listing gives the US Department of Defense and Veterans Affairs facilities access to Symvess for treating military personnel and other eligible patients, the company said.

Symvess received the US Food and Drug Administration's approval in December 2024 to treat extremity vascular trauma, Humacyte ( HUMA ) said.